Skip to main content
Equibles
INAB logo

INAB · In8bio, Inc.

Track INAB — free

Use INAB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.09 -0.01 (-0.91%) At close · Sep 1
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's business strategy, its existing cash of $18.0 million as of June 30, 2026 is not anticipated to fund the Company's projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company's ability to continue to operate as a going concern.”
View the 10-Q filed Aug 6, 2026
Market Cap
$10.75M
Shares
9.86M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.09 Open$1.10 Day$1.08–1.13 52W close$0.96–2.59 Avg vol 30d67K Short int140K · 1.4% float · 1.4d Short vol8% Last earningsMay 21, 2026 DataJun 2025–Sep 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Jun 6, 2025; bars on opposite sides are not compared.

Up next

Next earnings call
May 25, 2028 Est · unconfirmed · in 90 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.67
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −32%
below
Price vs 50-day avg −10%
below
RSI (14) 46
neutral
MACD trend Positive
52-week position 8%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +14%
trailing
6-month return −45%
trailing
YTD return −53%
this year
Relative strength −58%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.42% of float · ▲ +461.6% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
21 holders — mid 3-yr range
Squeeze score 50
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −63%
past year
ATR 8.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−32% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
46 Neutral
MACD trend
Positive Bullish
52-week position
8% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.42% of float · ▲ +461.6% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
21 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 8% Range high $3
vs 200-day avg -32% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INAB
In8bio, Inc.
this stock
$10.75M -53.4% — — 1.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +20.8% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.77B +6.7% +20.8% 19.7 2.3%
ARGX
Argenx SE
 $64.16B +22.3% — — 1.9%
CSLLY
Csl Ltd
 $59.51B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
21
% held
38.4%
Net QoQ
+37.0K sh
Top holder
Alyeska Investment Group,…
Held Float
View
Held by Funds
Fund positions
8
View
Short & Settlement
Short Interest Rising
Shares short
139.9K
Days to cover
1.4d
Change
+115.0K sh
View
Short Volume
Short vol %
8%
As of
Sep 1, 2026
Short Total
View
Fails to Deliver
FTD shares
607
Value
$716
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
71.9%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-19.4M
EPS diluted
$-4.44
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
10
View
Exempt Offerings
Offering
$40.2M
Filed
Dec 30, 2025
View
Earnings & Events
Earnings Calls
Last call
May 21, 2026
View
Investor Relations
Latest news
IN8bio Reports Inducement Grant U…
Published
Aug 10, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jun 6, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
INAB -6.8% +13.5% -45.2% -0.9% -53.4%
SPY -0.5% -1.2% +12.6% -0.7% +11.7%
vs SPY -6.3% +14.8% -57.9% -0.2% -65.1%
Key facts CIK 1740279 CUSIP 45674E208 13F (30d) 22 filings 22 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)